Abstract 204P
Background
Exploring the interaction between tissue and circulating immune descriptors may represent a critical step in our understanding of cancer immunity cycle to dissect distinct immunotherapy (IO) outcomes. Thus, we determined whether a comprehensive immune profiling, including tumor immune microenviroment (TIME) and peripheral blood (PB) might offer an “holistic” view of patient-specific immune background, potentially leading to new personalized therapeutic strategies.
Methods
On 59 consecutive IO-treated NSCLC patients, digital microscopy was employed on tissue samples to assess densities and spatial distribution (intratumor and stromal) of different Tumor-infiltrating lymphocytes (TILs) subpopulations (CD3+, CD4+-CD8+, PD-1+); peripheral blood (PB) samples were analyzed by Flow cytometry and immunenzymatic assay to determine circulating immune-inflammatory features. Statistical analyses were conducted to assess potential correlations between TIME and blood immune features.
Results
In our cohort of NSCLC patients, PB analysis revealed a significant direct correlation between the density of total and intratumor CD3+ TILs and the percentage of circulating CD3+ T cells. Moreover, higher CD8+ TILs correlated with an increase in circulating CD8+Ki67+ and a decrease in immunosuppressive Tregs (P<0.05). Cytokine analysis showed that IL-6 direclty correlated with TILs density, while IL-1β, IL-12p70, and IL-2 were linked to CD8/CD3 ratios (P<0.05). An inverse relationship was observed between PD-1/CD8 ratio and IL-1β, IFN-γ and TGF-β1, along with a negative correlation between IL-4 and PD-1+ TILs (P<0.05). Additionally, we found that PD-L1neg patients displayed higher levels of blood monocytes and Tregs. Increased PD-L1 expression correlated with higher CD3+ TILs, and a significant inverse relationship was noted between PD-L1 levels and the PD1-to-CD8 TILs ratio, suggesting that PD-L1+ cancer cells may inhibit cytotoxic T cells.
Conclusions
Our findings strongly suggest the existence of a complex crosstalk between tissue and circulating compartments in shaping the immune response against the tumor and likely the proneness to benefit from immunotherapy in advanced NSCLC patients.
Legal entity responsible for the study
University Hospital of Parma.
Funding
AIRC Associazione Italiana Ricerca sul Cancro.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
165P - TIGIT inhibition in non-small cell lung cancer: Meta-analysis of clinical efficacy and biomarker correlation
Presenter: Hashim Talib Hashim
Session: Poster Display session
Resources:
Abstract
168TiP - A phase I dose escalation/expansion study of GSK5764227 (GSK’227), a B7-homolog 3 (B7-H3) protein targeted antibody-drug conjugate (ADC), in patients with advanced solid tumours
Presenter: Giuseppe Curigliano
Session: Poster Display session
Resources:
Abstract
169TiP - Colorectal carcinoma: Low dose immunotherapy in upfront metastatic d/MMR patients (CLOUD study)
Presenter: Anant Ramaswamy
Session: Poster Display session
Resources:
Abstract
177P - Ubiquitous neoantigens as targets for T cell recognition in a patient with metastatic pancreatic neuroendocrine tumour
Presenter: Jean-Benoit Tanis
Session: Poster Display session
Resources:
Abstract
178P - Comprehensive immunophenotype analysis in anti-PD-1 antibody sensitive and resistant syngeneic mouse model unravels perforin-expressing CD4+T cells dominant cytolytic activity
Presenter: Hiroyuki Inoue
Session: Poster Display session
Resources:
Abstract
179P - Impact of exercise training on tumour-infiltrating T cells in human prostate cancer
Presenter: Louise Lehrskov
Session: Poster Display session
Resources:
Abstract
180P - Chronic circadian disruption promotes melanoma progression by interfering with NK cells
Presenter: Shuwen Xiao
Session: Poster Display session
Resources:
Abstract
181P - Intratumoral heterogeneity of immune infiltrate in leiomyosarcomas
Presenter: Iva Benesova
Session: Poster Display session
Resources:
Abstract
182P - Innovative nano-immunotherapy for modulating tumor-immune interactions and microbiome in pancreatic cancer
Presenter: Liane Moura
Session: Poster Display session
Resources:
Abstract
183P - CAIX negatively modulates inflammatory and anti-tumor immune responses
Presenter: Eliska Svastova
Session: Poster Display session
Resources:
Abstract